Home  |  Contact

Cellosaurus NT-3 (CVCL_VG81)

[Text version]
Cell line name NT-3
Accession CVCL_VG81
Resource Identification Initiative To cite this cell line use: NT-3 (RRID:CVCL_VG81)
Comments Doubling time: 10.9 +- 0.7 days (PubMed=29330294).
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
Sequence variations
  • Mutation; HGNC; 7010; MEN1; Simple; p.Thr541Ala (c.1621A>G); ClinVar=VCV000134640; Zygosity=Homozygous; Note=Probable SNP (PubMed=29330294).
Disease Pancreatic neuroendocrine tumor G2 (NCIt: C45835)
Neuroendocrine tumor of pancreas (ORDO: Orphanet_97253)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 33Y
Category Cancer cell line
Publications

PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163
Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G., Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M., Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M., Izbicki J.R., Lohse A.W., Schrader J.
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model.
Mol. Cancer Res. 16:496-507(2018)

CLPUB00598
Behrang Y.
Establishment and characterization of a new human, highly differentiated and functionally active tumor model of a pancreatic neuroendocrine tumor.
Thesis MD (2020), University of Hamburg, Germany

PubMed=36269546; DOI=10.1007/s13402-022-00727-z
Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M., Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J.
Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Cell. Oncol. (Dordr.) 45:1401-1419(2022)

Cross-references
Cell line databases/resources cancercelllines; CVCL_VG81
Encyclopedic resources Wikidata; Q54931073
Entry history
Entry creation14-May-2018
Last entry update05-Oct-2023
Version number10